Phase 2 N=63 A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
Psoriasis Vulgaris
Primary: Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene — 30.2; 30.0 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=300 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Gonadal Thrombosis
Primary: 6 Month Bleeding Rate — 0; 2.1 percentage of patients
N/A N=106 Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators
Congenital Hearing Loss
Primary: Number of Participants Who do Not Receive Diagnostic Audiological Testing (Aim 1) — 15; 8 Participants
N/A N=300 HIRREM Developmental Study
Sleep Initiation and Maintenance Disorders · Anxiety · Post-Traumatic Stress Disorder
Primary: Heart Rate Variability Standard Deviation of NN Intervals (SDNN) — 44.41 milliseconds
N/A N=90 A Comparative Study of Electric Toothbrushes for the Efficacy Plaque Removal and the Effect on Plaque Accumulation and Gingivitis.
Dental Plaque Induced Gingivitis · Dental Plaque
Primary: Plaque Index — 1.07; 1.19; 1.31; 1.11 units on a scale — p=0.1561
N/A N=63 Clinical Evaluation of Investigational Multifocal Contact Lenses
Visual Acuity
Primary: Overall Vision — 47.33 Units on a Scale
Phase 3 N=529 Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score — -22.48; -22.94; -24.22 units on a scale
Phase 3 N=11 Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
Severe Hemophilia A
Primary: Pharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C — 768.8; 671.9; 720.3 h*IU/dL
Phase 4 N=120 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
Urinary Bladder, Overactive · Urinary Incontinence
Primary: Change From Baseline in Daily Average Number of Urinary Incontinence Episodes — -2.99; -0.42 incontinence episodes per day — p=<.0001
Phase 1 N=24 A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
Migraine
Primary: Cmax — 9180.9; 5925.9; 15224.3; 3758.3 pg/mL
N/A N=610 Home Away From Home - Medical Outcomes
Acute Myeloid Leukemia · Neutropenia · Bacteremia
Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants
N/A N=38 Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
Ductal Breast Carcinoma in Situ · Invasive Ductal Breast Carcinoma · Invasive Lobular Breast Carcinoma
Primary: Number of Participants Who Are Adherent to the Diet Restriction — 28 participants
Phase 3 N=27 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
Pediatric Hypertension
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 19; 5 Participants
N/A N=154 Home Away From Home - Quality of Life Surveys
Pediatric Acute Myeloid Leukemia
Primary: Compare Differences in HRQOL Scores Between Outpatient Versus Inpatient Management — 70.1; 68.7 score on a scale
N/A N=105 A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants
Colitis, Ulcerative
Primary: Percentage of Participants With Clinical Response at Week 6 Based on Partial Mayo Score — 55.8 percentage of participants